Learn more →
Back to Expert Scholars
Translational Medicine / 转化医学Adjuvant BRAF/MEK Melanoma

Reinhard Dummer

MD

🏢University Hospital Zurich🌐Switzerland

Professor and Vice-Chairman of Dermatology

115
h-index
0
Key Papers
0
Key Contributions

👥Biography 个人简介

Reinhard Dummer led COMBI-AD establishing adjuvant dabrafenib plus trametinib for resected BRAF V600 mutant stage III melanoma, showing sustained long-term recurrence-free survival benefit. His work defined targeted therapy's role in adjuvant melanoma. He has shaped European melanoma treatment guidelines for over two decades.

Share:

🧪Research Fields 研究领域

COMBI-AD trial
adjuvant dabrafenib plus trametinib
BRAF V600 mutant resected melanoma
long-term RFS COMBI-AD
European melanoma leadership

🎓Key Contributions 主要贡献

Representative Works 代表性著作

📄Data Sources 数据来源

Last updated: 2026-04-01 | All information from publicly available academic sources

关注 Reinhard Dummer 的研究动态

Follow Reinhard Dummer's research updates

留下邮箱,当我们发布与 Reinhard Dummer(University Hospital Zurich)相关的新研究或访谈时,我们会通知你。

我们不会泄露你的信息,也不会发送无关内容。随时可以退订。

Explore More Experts

Discover the researchers shaping the future of cancer treatment